WCLC 2025 - Posters & ePosters-P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307

P3.13.34 Tarlatamab Efficacy and Safety in Chinese Patients with Advanced Small Cell Lung Cancer: Phase 2 DeLLphi-307

Pdf Summary

The Phase 2 DeLLphi-307 study evaluated the efficacy and safety of tarlatamab, a bispecific T-cell engager (BiTE) immunotherapy targeting DLL3, in 31 Chinese patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) in a third-line or later setting. Patients had a median age of 57, mostly male (84%), with a median of two prior therapies including platinum-based first-line and anti-PD-(L)1 treatments.<br /><br />Results showed promising efficacy: the confirmed objective response rate (ORR) was 39% (95% CI, 22–58), including one complete response and 11 partial responses. Disease control rate (DCR) was 61%. Median duration of response (DOR) and overall survival (OS) were not reached at a median follow-up of 2.8 and 3.8 months, respectively. Median progression-free survival (PFS) was 2.9 months. Notably, 92% of responders maintained ongoing responses at data cutoff.<br /><br />Tarlatamab exhibited a manageable safety profile. All patients experienced treatment-emergent adverse events (TEAEs), with 41.9% grade ≥3. The most common all-grade TEAEs were cytokine release syndrome (CRS) in 87.1%, anemia (38.7%), and neutropenia (29%). All CRS events were grade 1-2, occurred mainly after the first two doses, and resolved with supportive care and corticosteroids; no grade ≥3 CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) was reported. Serious treatment-related adverse events occurred in 22.6% with no treatment discontinuations due to adverse events.<br /><br />This study provides encouraging clinical evidence supporting tarlatamab as a new treatment option for Chinese patients with advanced SCLC who have exhausted prior therapies. Extended follow-up is ongoing to better characterize long-term response durability and survival benefits. The data highlight tarlatamab's potential to address an unmet need given limited approved third-line options and poor prognosis in this population.

Asset Subtitle

Qian Chu

Meta Tag

Speaker Qian Chu

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

tarlatamab

bispecific T-cell engager

DLL3

small cell lung cancer

extensive-stage SCLC

third-line treatment

objective response rate

cytokine release syndrome

treatment-emergent adverse events

Chinese patients